Allogene Therapeutics (ALLO) Stifel 2024 Healthcare Conference summary

Program overviews and innovation

• Three key programs: cema-cel in hematology, ALLO-329 in autoimmune, and ALLO-316 in solid tumors.

• Cema-cel leverages MRD positivity for patient selection, aiming to treat only those who need it.

• ALLO-329 targets both B-cells and CD70+ T-cells, aiming for broad autoimmune application.

• ALLO-316 shows promising efficacy in renal cell carcinoma, with ongoing expansion in high CD70 expressors.

• All programs utilize allogeneic CAR T technology for on-demand, off-the-shelf treatment.

Clinical trial progress and physician feedback

• High physician and investigator enthusiasm for cema-cel’s MRD-based approach.

• Over half of ALPHA3 clinical sites activated, with a majority in community cancer centers.

• Community oncologists value logistical ease and accessibility of allogeneic CAR T.

• ALPHA3 study design is flexible, with strong powering for event-free survival as the primary endpoint.

• Expansion phase for ALLO-316 targets 20 patients to refine efficacy and safety in high CD70 expressors.

Market opportunity and manufacturing

• Estimated 15,000 eligible frontline patients for cema-cel consolidation in the US and EU5.

• Autoimmune market projected to grow from $70B to $125B in 5–10 years.

• Manufacturing improvements include automated vial filling to increase capacity.

• ALLO-329 aims to reduce or eliminate lymphodepletion, broadening its use.

• Off-the-shelf availability is a key differentiator for all programs.